This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
ang ii | 2108 |
converting enzyme | 1202 |
angiotensin ii | 885 |
angiotensin system | 445 |
blood pressure | 417 |
heart failure | 360 |
ang i | 360 |
angiotensin converting | 250 |
ace inhibitors | 247 |
acute respiratory | 228 |
lung injury | 223 |
amino acid | 218 |
ace activity | 214 |
ace expression | 209 |
myocardial infarction | 184 |
amino acids | 177 |
mas receptor | 177 |
ii type | 170 |
angiotensin i | 169 |
ace ang | 165 |
type receptor | 162 |
ace inhibitor | 160 |
severe acute | 148 |
respiratory syndrome | 147 |
endothelial cells | 146 |
ii receptor | 138 |
ace inhibition | 131 |
smooth muscle | 129 |
cardiac hypertrophy | 121 |
angiotensin receptor | 120 |
spike protein | 114 |
nitric oxide | 111 |
acute lung | 110 |
ii levels | 109 |
mas axis | 109 |
hypertensive rats | 109 |
receptor blockers | 106 |
epithelial cells | 105 |
ace gene | 104 |
growth factor | 100 |
ace levels | 100 |
sars coronavirus | 98 |
respiratory distress | 97 |
kidney disease | 97 |
aldosterone system | 96 |
gene expression | 95 |
human ace | 95 |
angiotensinconverting enzyme | 94 |
oxidative stress | 93 |
distress syndrome | 89 |
diabetic nephropathy | 89 |
mrna expression | 88 |
coronavirus disease | 85 |
muscle cells | 82 |
ace protein | 82 |
cardiovascular disease | 82 |
left ventricular | 81 |
angiotensin peptides | 80 |
important role | 79 |
novel coronavirus | 76 |
cytokine storm | 76 |
animal models | 76 |
syndrome coronavirus | 75 |
receptor mas | 75 |
nervous system | 74 |
spontaneously hypertensive | 73 |
ang iv | 73 |
cord uid | 73 |
doc id | 73 |
endothelial dysfunction | 72 |
enzyme inhibition | 71 |
transgenic mice | 71 |
may also | 71 |
human angiotensin | 69 |
renin receptor | 68 |
renin angiotensin | 68 |
enzyme inhibitors | 67 |
knockout mice | 67 |
beneficial effects | 65 |
protein expression | 65 |
receptor antagonist | 65 |
ang iii | 64 |
mg kg | 63 |
neutral endopeptidase | 63 |
active site | 62 |
induced cardiac | 62 |
immune response | 61 |
brain ras | 61 |
inflammatory cytokines | 60 |
angiotensin type | 60 |
diabetes mellitus | 60 |
related carboxypeptidase | 59 |
clinical trials | 59 |
ace may | 58 |
induced lung | 58 |
vascular endothelial | 57 |
apelin ko | 57 |
present study | 56 |
blood flow | 56 |
ko mice | 56 |
cell proliferation | 55 |
podocyte injury | 55 |
coupled receptor | 53 |
plasma levels | 53 |
functional receptor | 53 |
pulmonary hypertension | 53 |
deficient mice | 52 |
vascular smooth | 52 |
ace mrna | 52 |
necrosis factor | 52 |
recombinant human | 52 |
stem cells | 51 |
protective effects | 51 |
receptor antagonists | 51 |
type diabetes | 50 |
increased ace | 50 |
cardiac function | 49 |
receptor axis | 49 |
crucial role | 49 |
bone marrow | 49 |
chronic kidney | 47 |
cardiovascular diseases | 47 |
heart function | 47 |
nlrp inflammasome | 46 |
viral entry | 46 |
novel angiotensin | 46 |
adipose tissue | 46 |
tumor necrosis | 46 |
endothelial cell | 46 |
central nervous | 46 |
mouse model | 45 |
human heart | 45 |
severe covid | 45 |
plasma ang | 45 |
biological activity | 45 |
increased ang | 43 |
lung tissue | 43 |
inhibitor therapy | 43 |
receptor blockade | 43 |
cell surface | 43 |
receptor blocker | 43 |
cardiac dysfunction | 43 |
protective role | 42 |
enzyme activity | 42 |
reninangiotensin system | 42 |
therapeutic target | 42 |
type i | 41 |
host cells | 41 |
kidney injury | 40 |
enzyme inhibitor | 40 |
ang tie | 40 |
immune system | 40 |
ii receptors | 40 |
mineralocorticoid receptor | 40 |
pregnant women | 40 |
lung cancer | 40 |
systematic review | 39 |
ace angiotensin | 39 |
cell growth | 39 |
cell membrane | 39 |
protein kinase | 39 |
reactive oxygen | 39 |
coronary artery | 38 |
also known | 38 |
previous studies | 38 |
viral infection | 38 |
cardiovascular system | 38 |
cardiac remodeling | 38 |
oxygen species | 38 |
cell death | 37 |
circulating ace | 37 |
cell lines | 37 |
solid phase | 37 |
ii infusion | 37 |
heart disease | 37 |
high glucose | 37 |
expression levels | 37 |
ace deficiency | 37 |
cardiac fibrosis | 37 |
biologically active | 37 |
inflammatory response | 36 |
enzyme gene | 36 |
blood vessels | 36 |
cell entry | 36 |
coronavirus infection | 35 |
pulmonary arterial | 35 |
vascular permeability | 35 |
transforming growth | 35 |
angiotensin iv | 35 |
significantly increased | 35 |
soluble ace | 35 |
arterial hypertension | 35 |
renin activity | 34 |
protective effect | 34 |
renal injury | 34 |
signaling pathways | 34 |
septic shock | 34 |
clinical characteristics | 34 |
ace knockout | 34 |
mass spectrometry | 34 |
binding domain | 34 |
viral replication | 34 |
functional expression | 33 |
rats angiotensin | 33 |
somatic ace | 33 |
peptide synthesis | 33 |
extracellular matrix | 33 |
pressure overload | 33 |
may contribute | 33 |
converts angiotensin | 33 |
disease severity | 33 |
recombinant ace | 33 |
ejection fraction | 33 |
high levels | 32 |
type ii | 32 |
tissue distribution | 32 |
binding site | 32 |
significantly higher | 32 |
potential therapeutic | 32 |
several studies | 32 |
cigarette smoke | 32 |
gastrointestinal tract | 32 |
cohort study | 31 |
infected patients | 31 |
local ras | 31 |
insulin resistance | 31 |
signal transduction | 31 |
rat model | 31 |
lung failure | 31 |
plasma membrane | 31 |
enzyme protects | 30 |
endothelial function | 30 |
cell volume | 30 |
endothelial growth | 30 |
nuclear factor | 30 |
angiotensin peptide | 30 |
hypertensive patients | 30 |
receptor binding | 30 |
increased expression | 30 |
clinical studies | 30 |
receptor activation | 30 |
clinical trial | 29 |
activated protein | 29 |
transgenic rats | 29 |
diabetic mice | 29 |
ace ace | 29 |
classical ras | 29 |
increased levels | 29 |
reduced ace | 29 |
human homolog | 29 |
proximal tubule | 29 |
experimental models | 29 |
ii formation | 29 |
molecular mechanisms | 29 |
plasma ace | 29 |
receptor gene | 29 |
side chain | 29 |
enzymatic activity | 29 |
ace receptor | 29 |
dependent manner | 29 |
first step | 28 |
receptor ace | 28 |
influenza virus | 28 |
recent study | 28 |
renal function | 28 |
diabetic kidney | 28 |
biological peptides | 28 |
avian influenza | 28 |
normal pregnancies | 28 |
proximal tubules | 28 |
enzyme angiotensin | 28 |
cancer cells | 28 |
congestive heart | 28 |
significantly reduced | 28 |
receptor stimulation | 28 |
system inhibitors | 28 |
pulmonary fibrosis | 28 |
oxide synthase | 27 |
catalytic activity | 27 |
acid residues | 27 |
lung fibrosis | 27 |
cardiac myocytes | 27 |
innate immune | 27 |
inflammatory effects | 27 |
critically ill | 27 |
cleavage site | 27 |
endogenous ligand | 27 |
natriuretic peptide | 27 |
pressure regulation | 27 |
brain tissue | 27 |
tie system | 27 |
highly expressed | 27 |
recent studies | 26 |
essential hypertension | 26 |
angiotensin receptors | 26 |
deletion polymorphism | 26 |
colitis severity | 26 |
ectodomain shedding | 26 |
per group | 26 |
raas axis | 26 |
severe cases | 26 |
essential regulator | 26 |
ace also | 26 |
ras system | 26 |
serum ace | 26 |
neurogenic hypertension | 26 |
molecular weight | 26 |
serine protease | 26 |
tissue injury | 26 |
ii production | 26 |
may lead | 26 |
ras components | 25 |
body weight | 25 |
room temperature | 25 |
renin inhibitors | 25 |
induced hypertension | 25 |
signaling pathway | 25 |
cell types | 25 |
protein levels | 25 |
crystal structure | 25 |
data suggest | 25 |
ang peptides | 25 |
null mice | 25 |
chronic heart | 25 |
renal disease | 25 |
among patients | 25 |
also found | 24 |
novel therapeutic | 24 |
renin inhibitor | 24 |
pulmonary vascular | 24 |
risk factors | 24 |
alveolar epithelial | 24 |
protease inhibitor | 24 |
building blocks | 24 |
western blot | 24 |
mrna levels | 24 |
ii signaling | 24 |
liver fibrosis | 24 |
lung tumor | 24 |
glomerular filtration | 24 |
cardiac fibroblasts | 24 |
ii induces | 24 |
organ damage | 24 |
arterial pressure | 24 |
control group | 24 |
antimicrobial peptides | 24 |
understanding sars | 24 |
catalytic domain | 24 |
ventrolateral medulla | 23 |
ischemia reperfusion | 23 |
cardiac angiotensin | 23 |
active sites | 23 |
artery disease | 23 |
coronavirus spike | 23 |
high blood | 23 |
generate ang | 23 |
vascular remodeling | 23 |
adrenal gland | 23 |
infected mice | 23 |
retrospective cohort | 23 |
cov infection | 23 |
ventricular dysfunction | 23 |
rights reserved | 23 |
statistically significant | 23 |
hepatic fibrosis | 23 |
cellular hypertrophy | 23 |
results showed | 23 |
brain renin | 23 |
raas components | 23 |
prorenin receptor | 23 |
cardiovascular effects | 23 |
transcription factor | 23 |
sars pathogenesis | 23 |
high affinity | 23 |
results suggest | 23 |
receptor expression | 23 |
proteolytic cleavage | 22 |
treated mice | 22 |
diabetic rats | 22 |
spike glycoprotein | 22 |
patients infected | 22 |
statistical significance | 22 |
clinical course | 22 |
failing human | 22 |
acute myocardial | 22 |
side effects | 22 |
plasma renin | 22 |
receptor type | 22 |
human renin | 22 |
clinical outcomes | 22 |
vitro studies | 22 |
studies using | 22 |
ventricular hypertrophy | 22 |
previous study | 22 |
critical role | 22 |
lung diseases | 22 |
immune responses | 22 |
amyotrophic lateral | 22 |
smoke exposure | 22 |
ace ratio | 22 |
united states | 22 |
insensitive carboxypeptidase | 22 |
lateral sclerosis | 22 |
sympathetic nervous | 21 |
hospitalized patients | 21 |
rat brain | 21 |
receptor subtypes | 21 |
endoplasmic reticulum | 21 |
uric acid | 21 |
angiotensin iii | 21 |
clinical evidence | 21 |
severe pneumonia | 21 |
reperfusion injury | 21 |
circulating ang | 21 |
catenin signaling | 21 |
key role | 21 |
inflammatory cytokine | 21 |
significantly decreased | 21 |
respiratory failure | 21 |
ace shedding | 21 |
signalling pathways | 21 |
lung disease | 21 |
cardiovascular function | 21 |
ace overexpression | 21 |
essential role | 21 |
pathological conditions | 21 |
liver disease | 21 |
binding affinity | 21 |
form ang | 21 |
produce ang | 21 |
innate immunity | 21 |
adverse effects | 20 |
inhibitory activity | 20 |
gene transfer | 20 |
like ace | 20 |
induced acute | 20 |
ace deletion | 20 |
ace cleaves | 20 |
tissue angiotensin | 20 |
cancer cell | 20 |
proximal tubular | 20 |
ras activation | 20 |
intensive care | 20 |
potential role | 20 |
human tissues | 20 |
risk factor | 20 |
human lung | 20 |
enzyme type | 20 |
hypertensive rat | 20 |
spike proteins | 20 |
central role | 20 |
chain hetes | 20 |
genetic deletion | 20 |
classical raas | 20 |
catalytically active | 20 |
secondary structure | 20 |
orally active | 20 |
multiple comparisons | 20 |
tissue damage | 20 |
cytokine release | 20 |
ii effects | 19 |
virus infection | 19 |
bovine serum | 19 |
therapeutic targets | 19 |
glomerular injury | 19 |
mouse models | 19 |
induced pulmonary | 19 |
vascular inflammation | 19 |
wt mice | 19 |
previously described | 19 |
gs bs | 19 |
disease progression | 19 |
bs type | 19 |
first time | 19 |
circulating ras | 19 |
organ dysfunction | 19 |
previously reported | 19 |
exposed rats | 19 |
significant differences | 19 |
mice angiotensin | 19 |
western blotting | 19 |
mas receptors | 19 |
patients treated | 19 |
cellular ace | 19 |
receptor subtype | 19 |
significant difference | 19 |
time pcr | 19 |
well established | 19 |
human coronavirus | 19 |
cyclic peptides | 19 |
may explain | 19 |
taken together | 19 |
receptor agonist | 19 |
hypertension angiotensin | 19 |
vascular endothelium | 19 |
another study | 19 |
angiotensin systems | 19 |
ii treatment | 19 |
physiological functions | 19 |
like receptor | 19 |
cell survival | 19 |
insertion deletion | 19 |
ii generation | 18 |
platelet aggregation | 18 |
viral rna | 18 |
peptide analogues | 18 |
cell type | 18 |
endogenous ang | 18 |
map kinase | 18 |
mesangial cells | 18 |
kinin system | 18 |
peptide levels | 18 |
plasminogen activator | 18 |
proinflammatory cytokines | 18 |
myocardial fibrosis | 18 |
human airway | 18 |
metabolic syndrome | 18 |
homologue ace | 18 |
may play | 18 |
db db | 18 |
urinary levels | 18 |
cell apoptosis | 18 |
treated group | 18 |
target cells | 18 |
normal lung | 18 |
clinical data | 18 |
also observed | 18 |
dependent mechanism | 18 |
rat heart | 18 |
organ failure | 18 |
active peptides | 18 |
significantly different | 18 |
induced diabetic | 18 |
receptor angiotensin | 18 |
ii stimulates | 18 |
membrane fusion | 18 |
healthy individuals | 18 |
brain angiotensin | 18 |
portal pressure | 18 |
bs patients | 18 |
isolated perfused | 18 |
airway epithelial | 17 |
serum ang | 17 |
therapeutic potential | 17 |
vasodilatory shock | 17 |
authors declare | 17 |
may increase | 17 |
substrate specificity | 17 |
antimicrobial activity | 17 |
evidence suggests | 17 |
antihypertensive effects | 17 |
metabolic stability | 17 |
coronavirus infections | 17 |
brain barrier | 17 |
aldosterone synthase | 17 |
natriuretic peptides | 17 |
bound ace | 17 |
left ventricle | 17 |
kidney diseases | 17 |
tumor tissue | 17 |
podocyte apoptosis | 17 |
novel peptide | 17 |
suppressed ang | 17 |
control rats | 17 |
soluble form | 17 |
increased risk | 17 |
plasma kallikrein | 17 |
mice showed | 17 |
db mice | 17 |
injury angiotensin | 17 |
transmembrane protein | 17 |
performed using | 17 |
acute kidney | 17 |
circulating levels | 17 |
type mice | 17 |
mice lacking | 17 |
acid transporter | 17 |
protecting groups | 17 |
analysis revealed | 17 |
healthy controls | 17 |
arb use | 17 |
arachidonic acid | 17 |
phase peptide | 17 |
dawley rats | 17 |
fold higher | 17 |
detrimental effects | 16 |
intestinal inflammation | 16 |
two different | 16 |
glomerular diseases | 16 |
aldosterone secretion | 16 |
adhesion molecules | 16 |
ncov infection | 16 |
deleterious effects | 16 |
failure patients | 16 |
ras blockade | 16 |
inflammatory mediators | 16 |
biological effects | 16 |
cardioprotective effects | 16 |
systolic blood | 16 |
inflammatory responses | 16 |
regulated aminopeptidase | 16 |
higher risk | 16 |
animal model | 16 |
multiple organ | 16 |
endogenous apelin | 16 |
viral invasion | 16 |
skeletal muscle | 16 |
stem cell | 16 |
human recombinant | 16 |
side chains | 16 |
complement system | 16 |
tissue ras | 16 |
tyrosine kinase | 16 |
tubular cells | 16 |
widely used | 16 |
ras inhibitors | 16 |
one study | 16 |
significant reduction | 16 |
losartan treatment | 16 |
pivotal role | 16 |
vascular resistance | 16 |
type receptors | 16 |
viral particles | 16 |
wide variety | 16 |
local renin | 16 |
extracellular domain | 16 |
ii ang | 16 |
small intestine | 16 |
ill patients | 16 |
exogenous ang | 16 |
neutral amino | 16 |
renal angiotensin | 16 |
drug design | 16 |
increased blood | 16 |
way anova | 16 |
animal studies | 15 |
pulmonary artery | 15 |
respiratory system | 15 |
generating ang | 15 |
target organs | 15 |
clinical features | 15 |
serine proteases | 15 |
cyclic peptide | 15 |
decreased expression | 15 |
solid support | 15 |
based drug | 15 |
may provide | 15 |
ace null | 15 |
ventricular tachycardia | 15 |
ace might | 15 |
inflammatory cells | 15 |
cells angiotensin | 15 |
adhesion molecule | 15 |
care unit | 15 |
renal ace | 15 |
ace plays | 15 |
atrial fibrillation | 15 |
two active | 15 |
serum levels | 15 |
might also | 15 |
also showed | 15 |
cell adhesion | 15 |
myocardial ischemia | 15 |
vascular injury | 15 |
molecular dynamics | 15 |
mediates regulated | 15 |
viral load | 15 |
plasma angiotensin | 15 |
masr axis | 15 |
human cells | 15 |
system blockers | 15 |
ii stimulation | 15 |
negative regulator | 15 |
whereas ace | 15 |
active renin | 15 |
brush border | 15 |
cardiac contractility | 15 |
rat hearts | 15 |
renal ang | 15 |
peptide metabolism | 15 |
higher levels | 15 |
portal hypertension | 15 |
peptide ang | 15 |
cell signaling | 15 |
ace concentration | 15 |
subfornical organ | 15 |
regulated ectodomain | 15 |
basement membrane | 15 |
activator inhibitor | 15 |
pressure elevation | 15 |
cardiomyocyte hypertrophy | 14 |
viral infections | 14 |
inflammatory drugs | 14 |
normal pregnancy | 14 |
lipid accumulation | 14 |
i converting | 14 |
mice per | 14 |
host cell | 14 |
binding sites | 14 |
human podocytes | 14 |
receptor signaling | 14 |
also associated | 14 |
whereas ang | 14 |
study showed | 14 |
ethics committee | 14 |
cell culture | 14 |
respiratory tract | 14 |
daily i | 14 |
expression profiling | 14 |
cell viability | 14 |
heart association | 14 |
two peptides | 14 |
ischaemic heart | 14 |
new therapeutic | 14 |
cells expressing | 14 |
structural basis | 14 |
increased angiotensin | 14 |
genetic ace | 14 |
vascular leakage | 14 |
peptide angiotensin | 14 |
chronic angiotensin | 14 |
aldosterone levels | 14 |
current evidence | 14 |
converts ang | 14 |
tumor cells | 14 |
findings suggest | 14 |
intracellular signaling | 14 |
controlled trial | 14 |
renin prorenin | 14 |
extracellular signal | 14 |
tissue factor | 14 |
wide range | 14 |
phase synthesis | 14 |
circulating renin | 14 |
middle east | 14 |
immune cells | 14 |
expressing cells | 14 |
ace transgenic | 14 |
analyzed using | 14 |
urinary ace | 14 |
ii accumulation | 14 |
rat models | 14 |
rostral ventrolateral | 14 |
lung inflammation | 14 |
heart rate | 14 |
high concentrations | 14 |
podocyte loss | 14 |
experimental studies | 14 |
ventricular remodeling | 14 |
binding protein | 14 |
new coronavirus | 14 |
native peptide | 14 |
major role | 14 |
glucose transporter | 13 |
ex vivo | 13 |
new class | 13 |
enzyme homologue | 13 |
producing ang | 13 |
progenitor cells | 13 |
sga pregnancies | 13 |
transcription factors | 13 |
kinin peptides | 13 |
low levels | 13 |
knockout mouse | 13 |
potent vasoconstrictor | 13 |
cell rna | 13 |
vascular dysfunction | 13 |
tissue ang | 13 |
ras activity | 13 |
cell line | 13 |
acid sequence | 13 |
cardiac ace | 13 |
tissue ace | 13 |
vascular disease | 13 |
different tissues | 13 |
feedback loop | 13 |
forming activity | 13 |
density lipoprotein | 13 |
cultured human | 13 |
physiological roles | 13 |
peptide sequence | 13 |
metabolic alkalosis | 13 |
gene polymorphisms | 13 |
ii pneumocytes | 13 |
ng ml | 13 |
two main | 13 |
disease control | 13 |
chemoattractant protein | 13 |
system angiotensin | 13 |
juxtaglomerular cells | 13 |
mast cell | 13 |
measured using | 13 |
bl mice | 13 |
studies suggest | 13 |
pressure control | 13 |
arb therapy | 13 |
sars virus | 13 |
total rna | 13 |
kidney damage | 13 |
filtration barrier | 13 |
type diabetic | 13 |
local tissue | 13 |
terminal domain | 13 |
randomized controlled | 13 |
plasma aldosterone | 13 |
ii may | 13 |
transmembrane domain | 13 |
disulfide bridges | 13 |
glomerular podocytes | 13 |
significantly lower | 13 |
receptors mediate | 13 |
cardiac phenotype | 13 |
resistant hypertension | 13 |
beneficial effect | 13 |
viral spike | 13 |
studies showed | 13 |
recently reported | 13 |
hete metabolites | 13 |
tissue kallikrein | 13 |
sudden death | 13 |
angiotensin aldosterone | 13 |
engineered human | 13 |
cd cd | 13 |
gestational age | 13 |
function angiotensin | 13 |
entry receptor | 13 |
increased plasma | 13 |
hypertensive mice | 13 |
east respiratory | 13 |
growth factors | 13 |
entry depends | 12 |
systemic inflammation | 12 |
liver injury | 12 |
fatty acids | 12 |
structural studies | 12 |
controlled trials | 12 |
sfrp expression | 12 |
ros production | 12 |
recombinant angiotensin | 12 |
ras plays | 12 |
cardiac tissue | 12 |
protein synthesis | 12 |
podocyte damage | 12 |
complement cascade | 12 |
receptor antagonism | 12 |
tie signalling | 12 |
coupled receptors | 12 |
proteolytic activation | 12 |
human plasma | 12 |
significant role | 12 |
renin gene | 12 |
feb suppressed | 12 |
hydrogen bond | 12 |
adult inpatients | 12 |
gene polymorphism | 12 |
proven protease | 12 |
metabolite formation | 12 |
rat kidney | 12 |
vasopressin release | 12 |
acid transporters | 12 |
liquid chromatography | 12 |
blood coagulation | 12 |
current study | 12 |
may serve | 12 |
acei arb | 12 |
post hoc | 12 |
cl cotransporter | 12 |
like stem | 12 |
activity relationship | 12 |
protease tmprss | 12 |
renal tubular | 12 |
dependent hypertension | 12 |
heart weight | 12 |
membrane protein | 12 |
murine model | 12 |
induced cellular | 12 |
commercially available | 12 |
serum angiotensin | 12 |
induced vascular | 12 |
therapeutic strategies | 12 |
well known | 12 |
small embryonic | 12 |
lung function | 12 |
collecting duct | 12 |
also shown | 12 |
pulmonary diseases | 12 |
particular interest | 12 |
alpha convertase | 12 |
interstitial fibrosis | 12 |
aldosterone concentration | 12 |
click chemistry | 12 |
much higher | 12 |
diabetic complications | 12 |
critical illness | 12 |
cellular receptor | 12 |
immune complexes | 12 |
decreased ang | 12 |
ii also | 12 |
dss i | 12 |
pediatric patients | 12 |
endothelial nitric | 12 |
effects via | 12 |
high concentration | 12 |
ras axis | 12 |
antihypertensive agents | 12 |
clinically proven | 12 |
inflammatory diseases | 12 |
ii mediates | 12 |
classical axis | 12 |
cancer risk | 12 |
american heart | 12 |
mononuclear cells | 12 |
inhibitor treatment | 12 |
pathological changes | 12 |
mouth disease | 12 |
transmembrane protease | 12 |
subsequent studies | 12 |
therapeutic implications | 12 |
may result | 12 |
tissues using | 12 |
renal fibrosis | 12 |
mouse kidney | 12 |
renal tubules | 12 |
induced podocyte | 12 |
chronic cigarette | 12 |
pulmonary edema | 12 |
creative commons | 12 |
system blockade | 12 |
ahf patients | 12 |
failing heart | 12 |
actin cytoskeleton | 12 |
disease angiotensin | 12 |
resveratrol alone | 12 |
high risk | 12 |
ace activation | 11 |
cardiovascular physiology | 11 |
birth weight | 11 |
systemic ras | 11 |
chain reaction | 11 |
water retention | 11 |
sex differences | 11 |
intracellular signalling | 11 |
determined using | 11 |
cardiovascular actions | 11 |
peptide bond | 11 |
ms ms | 11 |
single amino | 11 |
elevated blood | 11 |
assay kit | 11 |
increases ace | 11 |
elevated plasma | 11 |
drug discovery | 11 |
also promotes | 11 |
selective inhibitors | 11 |
cellular uptake | 11 |
monocyte chemoattractant | 11 |
two enzymes | 11 |
expressing ace | 11 |
ulcerative colitis | 11 |
induced heart | 11 |
dependent pathways | 11 |
terminal catalytic | 11 |
increased urinary | 11 |
increased production | 11 |
ii binds | 11 |
human angiotensinconverting | 11 |
lung damage | 11 |
inhibit ace | 11 |
following myocardial | 11 |
arg bradykinin | 11 |
expression may | 11 |
transgenic mouse | 11 |
therapeutic strategy | 11 |
normal pregnant | 11 |
atrial natriuretic | 11 |
enzymerelated carboxypeptidase | 11 |
nep may | 11 |
structural proteins | 11 |
therapeutic role | 11 |
patients receiving | 11 |
catenin pathway | 11 |
even though | 11 |
fetal bovine | 11 |
expression level | 11 |
muscle cell | 11 |
specific inhibitors | 11 |
clinical effects | 11 |
sequence homology | 11 |
cellular responses | 11 |
ras pathway | 11 |
kidney function | 11 |
cord blood | 11 |
increasing ace | 11 |
gut dysbiosis | 11 |
prostate cancer | 11 |
negative feedback | 11 |
converting enzymerelated | 11 |
hypotensive effect | 11 |
ventricular systolic | 11 |
glomerular basement | 11 |
therapeutic agents | 11 |
cardiac ang | 11 |
peptide fragments | 11 |
alveolar macrophages | 11 |
significant decrease | 11 |
viral attachment | 11 |
least two | 11 |
brain regions | 11 |
bioactive peptides | 11 |
urinary excretion | 11 |
human endothelial | 11 |
molecular biology | 11 |
biological functions | 11 |
coronary arteries | 11 |
via mas | 11 |
research ethics | 11 |
pressure responses | 11 |
stranded rna | 11 |
diminazene aceturate | 11 |
cell membranes | 11 |
failure angiotensin | 11 |
amide bond | 11 |
increase ace | 11 |
multiple sclerosis | 11 |
specific ace | 11 |
blot analysis | 11 |
terminal residue | 11 |
tissue renin | 11 |
possible role | 11 |
infected cells | 11 |
protein kinases | 11 |
los niveles | 11 |
akita mice | 11 |
glycation end | 11 |
carboxypeptidase angiotensin | 11 |
fatty acid | 11 |
high level | 11 |
hematopoietic stem | 11 |
human vascular | 11 |
attenuates angiotensin | 11 |
protein interactions | 11 |
syncytial virus | 11 |
healthy volunteers | 11 |
degrades ang | 11 |
pg ml | 11 |
tissue levels | 11 |
data indicate | 11 |
higher concentrations | 11 |
mas pathway | 11 |
tumor growth | 11 |
via angiotensin | 11 |
phase ii | 11 |
nucleus tractus | 11 |
angiotensinogen gene | 11 |
cellular levels | 11 |
cardiovascular events | 11 |
ii concentration | 11 |
polymerase chain | 11 |
supplementary material | 11 |
many tissues | 11 |
potential target | 11 |
pulmonary disease | 11 |
cardiac injury | 11 |
increase ang | 10 |
two distinct | 10 |
important roles | 10 |
significant increase | 10 |
ang peptide | 10 |
human kidney | 10 |
commonly used | 10 |
respiratory disease | 10 |
induced tgf | 10 |
neprilysin inhibitor | 10 |
platelet activation | 10 |
diabetic patients | 10 |
breast cancer | 10 |
functional groups | 10 |
matrix proteins | 10 |
active peptide | 10 |
ace activators | 10 |
harmful effects | 10 |
increased activity | 10 |
heart ventricles | 10 |
better understanding | 10 |
preserved ejection | 10 |
inhibits growth | 10 |
induced pah | 10 |
tissue sites | 10 |
informed consent | 10 |
inhibitory effects | 10 |
direct renin | 10 |
binding proteins | 10 |
pulmonary arteries | 10 |
advanced glycation | 10 |
wild type | 10 |
factor receptor | 10 |
chronic liver | 10 |
aldosterone production | 10 |
large number | 10 |
may promote | 10 |
emerging evidence | 10 |
coronavirus nl | 10 |
disease states | 10 |
rheumatoid arthritis | 10 |
blood pressures | 10 |
colitis induction | 10 |
results indicated | 10 |
mechanical ventilation | 10 |
forming enzymes | 10 |
rodent models | 10 |
renal perfusion | 10 |
closely related | 10 |
severe disease | 10 |
potential treatment | 10 |
intracellular calcium | 10 |
myocardial injury | 10 |
two isoforms | 10 |
diabetic renal | 10 |
ras may | 10 |
enhanced expression | 10 |
inhibitory effect | 10 |
metabolic disorders | 10 |
hypotensive effects | 10 |
antithrombotic effect | 10 |
angiotensinogen mrna | 10 |
ace functions | 10 |
inflammatory bowel | 10 |
infection may | 10 |
type angiotensin | 10 |
mice treated | 10 |
lipid metabolism | 10 |
cardioprotective effect | 10 |
venous thromboembolism | 10 |
severe heart | 10 |
mechanical stress | 10 |
circular dichroism | 10 |
foot processes | 10 |
physiological conditions | 10 |
peptide substrates | 10 |
isolated rat | 10 |
evidence indicates | 10 |
renal failure | 10 |
mesenchymal transition | 10 |
ace polymorphisms | 10 |
raas genes | 10 |
widely expressed | 10 |
short half | 10 |
induced ace | 10 |
formation rate | 10 |
elevated ang | 10 |
renal cortex | 10 |
epithelial cell | 10 |
amino group | 10 |
may help | 10 |
early stages | 10 |
menstrual cycle | 10 |
probably due | 10 |
reduced renal | 10 |
inhibition may | 10 |
world health | 10 |
glucose uptake | 10 |
induced colitis | 10 |
cardiovascular risk | 10 |
pressure response | 10 |
chemical synthesis | 10 |
respiratory syncytial | 10 |
mediated effects | 10 |
data analysis | 10 |
autoimmune diseases | 10 |
alzheimer disease | 10 |
influenza viruses | 10 |
mediated reduction | 10 |
health organization | 10 |
paraventricular nucleus | 10 |
european society | 10 |
safety profile | 10 |
direct effect | 10 |
cells may | 10 |
insulin sensitivity | 10 |
sequence identity | 10 |
structural analysis | 10 |
also increased | 10 |
nadph oxidase | 10 |
analysis showed | 10 |
sodium retention | 10 |
terminal amino | 10 |
ser thr | 10 |
cleaves ang | 10 |
soluble human | 10 |
local angiotensin | 10 |
ischemic stroke | 10 |
cd cells | 10 |
carboxyl group | 10 |
renin receptors | 10 |
electrolyte balance | 10 |
inhibitor arb | 10 |
perfused rat | 10 |
lung adenocarcinoma | 10 |
vascular complications | 10 |
inflammatory factors | 10 |
markedly increased | 10 |
vascular beds | 10 |
regulatory role | 10 |
aortic smooth | 10 |
circulating angiotensin | 10 |
increasing evidence | 10 |
whether ace | 10 |
mortality rate | 10 |
inhibitor binding | 10 |
two axes | 10 |
small molecule | 10 |
chemical stability | 10 |
aortic fibrosis | 10 |
may cause | 10 |
renoprotective effects | 10 |
therapeutic benefits | 10 |
virus entry | 10 |
er stress | 10 |
early gestation | 9 |
induced aortic | 9 |
gene family | 9 |
porcine coronary | 9 |
negatively charged | 9 |
mm nacl | 9 |
coronary heart | 9 |
dipeptidyl carboxypeptidase | 9 |
ii via | 9 |
length human | 9 |
precursor protein | 9 |
gene encoding | 9 |
related protein | 9 |
plasma samples | 9 |
statistical analysis | 9 |
systolic dysfunction | 9 |
hypertensive subjects | 9 |
airway epithelia | 9 |
signal peptide | 9 |
catalytic efficiency | 9 |
renal dysfunction | 9 |
filtration rate | 9 |
epicardial adipose | 9 |
cell swelling | 9 |
different organs | 9 |
treated apelin | 9 |
helical conformation | 9 |
sympathetic nerve | 9 |
soluble angiotensin | 9 |
ace internalization | 9 |
solitary tract | 9 |
gene deletion | 9 |
determine whether | 9 |
santa cruz | 9 |
antihypertensive drugs | 9 |
heart block | 9 |
end products | 9 |
ii synthesis | 9 |
endogenous angiotensin | 9 |
future studies | 9 |
acid residue | 9 |
endosome system | 9 |
human angiogenin | 9 |
system components | 9 |
predominantly expressed | 9 |
therapeutic intervention | 9 |
previous results | 9 |
prolyl endopeptidase | 9 |
ace contains | 9 |
chain hete | 9 |
renovascular hypertension | 9 |
binding motif | 9 |
new organ | 9 |
beneficial role | 9 |
ace function | 9 |
using one | 9 |
functional roles | 9 |
peptide inhibitor | 9 |
enzyme attenuates | 9 |
recently described | 9 |
specific cell | 9 |
ras systems | 9 |
pulmonary ras | 9 |
protecting group | 9 |
water transport | 9 |
mice exhibit | 9 |
fatal outcomes | 9 |
antagonizes ang | 9 |
ace activator | 9 |
tubular epithelial | 9 |
raas axes | 9 |
provided evidence | 9 |
sars receptor | 9 |
clinical relevance | 9 |
cell migration | 9 |
higher plasma | 9 |
correlated inversely | 9 |
renal blood | 9 |
cdna library | 9 |
blood cells | 9 |
clinical benefits | 9 |
chronic ace | 9 |
assay buffer | 9 |
podocyte hypertrophy | 9 |
lower ace | 9 |
pathogenic avian | 9 |
inflammatory lung | 9 |
hfmd cases | 9 |
myocardial remodeling | 9 |
ace via | 9 |
enzyme overexpression | 9 |
critical care | 9 |
foot process | 9 |
including ace | 9 |
normotensive rats | 9 |
without affecting | 9 |
accepted article | 9 |
blood samples | 9 |
right ventricular | 9 |
acute phase | 9 |
critical conditions | 9 |
pathological findings | 9 |
converting enzymes | 9 |
highly specific | 9 |
i receptor | 9 |
human brain | 9 |
convert ang | 9 |
decreased ace | 9 |
axis activation | 9 |
infectious diseases | 9 |
angiotensin generation | 9 |
significantly inhibited | 9 |
protective arm | 9 |
mice show | 9 |
activity assay | 9 |
infarct size | 9 |
vivo study | 9 |
positively correlated | 9 |
last decade | 9 |
like receptors | 9 |
myocardial ace | 9 |
recombinant soluble | 9 |
associated protein | 9 |
th cells | 9 |
peripheral blood | 9 |
ii degradation | 9 |
receptors may | 9 |
treated rats | 9 |
intrarenal renin | 9 |
ang variants | 9 |
apelin knockout | 9 |
inhibitors may | 9 |
cardiac effects | 9 |
downregulate ace | 9 |
conscious rats | 9 |
gel electrophoresis | 9 |
mm tris | 9 |
fibrosis angiotensin | 9 |
pathways angiotensin | 9 |
decompensated heart | 9 |
baroreflex sensitivity | 9 |
experimental model | 9 |
kg dose | 9 |
new angiotensin | 9 |
growth restriction | 9 |
neprilysin inhibition | 9 |
naturally occurring | 9 |
inhibits angiotensin | 9 |
local production | 9 |
receptor knockout | 9 |
salt hypertension | 9 |
positive feedback | 9 |
ii cell | 9 |
ev infection | 9 |
renal diseases | 9 |
viral loads | 9 |
pathological cardiac | 9 |
alternative raas | 9 |
epidermal growth | 9 |
inflammatory reactions | 9 |
connective tissue | 9 |
evidence supports | 9 |
reduced ang | 9 |
may represent | 9 |
newly synthesized | 9 |
rat angiotensin | 9 |
remains unclear | 9 |
cigarette smoking | 9 |
endothelial damage | 9 |
apical surface | 9 |
raas inhibitors | 9 |
well tolerated | 9 |
reach statistical | 9 |
gene transcription | 9 |
increased susceptibility | 9 |
complement activation | 9 |
biological properties | 9 |
fractional shortening | 9 |
coronavirus pneumonia | 9 |
recent years | 9 |
protein coupled | 9 |
high ang | 9 |
improves endothelial | 9 |
cerebrospinal fluid | 9 |
angiotensin metabolism | 9 |
intracellular ang | 9 |
cardiotoxic mid | 9 |
activated ras | 9 |
extracellular space | 9 |
releasing peptide | 9 |
inflammasome activation | 9 |
downregulated connexins | 9 |
arb treatment | 9 |
pulmonary hypertensive | 9 |
renin secretion | 9 |
blood volume | 9 |
randomized clinical | 9 |
ion channels | 9 |
elevated levels | 9 |
rna expression | 9 |
membrane bound | 9 |
functional significance | 9 |
mouse hearts | 9 |
normal cardiac | 9 |
regulates ace | 9 |
expression via | 9 |
terminal region | 8 |
acid transport | 8 |
transfected cells | 8 |
drug development | 8 |
hemodynamic effects | 8 |
baroreceptor reflex | 8 |
dipolar cycloaddition | 8 |
mas proto | 8 |
sympathetic activity | 8 |
physiological role | 8 |
cytokine production | 8 |
ace insertion | 8 |
activity ace | 8 |
like growth | 8 |
group showed | 8 |
mediates angiotensin | 8 |
lipoic acid | 8 |
drugs targeting | 8 |
peptide backbone | 8 |
transduction mechanisms | 8 |
quantitative mrna | 8 |
proteolytic enzymes | 8 |
novel homologue | 8 |
severe hfmd | 8 |
cardiovascular complications | 8 |
chinese center | 8 |
diseases angiotensin | 8 |
study also | 8 |
mesenchymal stem | 8 |
adrenal glands | 8 |
two homologous | 8 |
specific receptor | 8 |
mesenteric arteries | 8 |
podocyte detachment | 8 |
disulfide bonds | 8 |
mental retardation | 8 |
human umbilical | 8 |
cardiac muscle | 8 |
several reports | 8 |
molecular modelling | 8 |
levels may | 8 |
eca en | 8 |
factor alpha | 8 |
peptide inhibitors | 8 |
podocyte injuries | 8 |
membranal ace | 8 |
penetrating peptides | 8 |
ace reduces | 8 |
studies showing | 8 |
opposite effects | 8 |
plasma level | 8 |
specific inhibitor | 8 |
synthase inhibition | 8 |
via activation | 8 |
time points | 8 |
male mice | 8 |
also contribute | 8 |
lupus nephritis | 8 |
rat proximal | 8 |
indel polymorphism | 8 |
whether ang | 8 |
bradykinin potentiation | 8 |
highly pathogenic | 8 |
myosin heavy | 8 |
accentuates vascular | 8 |
therapeutic options | 8 |
inflammatory markers | 8 |
organ dysfunctions | 8 |
rho kinase | 8 |
glomerular sclerosis | 8 |
ii increases | 8 |
might play | 8 |
hoc test | 8 |
apoe knockout | 8 |
induced cell | 8 |
higher expression | 8 |
induced vasodilation | 8 |
induce podocyte | 8 |
murine vsels | 8 |
oxide release | 8 |
mrna level | 8 |
national health | 8 |
secreted frizzled | 8 |
different cell | 8 |
amyloid fibrils | 8 |
ras cascade | 8 |
transgenic animals | 8 |
selective ace | 8 |
nmr spectroscopy | 8 |
hypertensive nephrosclerosis | 8 |
catalytic properties | 8 |
releasing hormone | 8 |
blood vessel | 8 |
buffered saline | 8 |
upper respiratory | 8 |
although ace | 8 |
ii alone | 8 |
pathway angiotensin | 8 |
rat liver | 8 |
also play | 8 |
putative receptor | 8 |
tertiary structure | 8 |
monoclonal antibodies | 8 |
peptide corresponding | 8 |
fluid homeostasis | 8 |
surface area | 8 |
increased glomerular | 8 |
specific amino | 8 |
fetal growth | 8 |
high mortality | 8 |
enzyme accelerates | 8 |
second messenger | 8 |
antimicrobial peptide | 8 |
organic solvents | 8 |
adverse events | 8 |
studies indicate | 8 |
previously shown | 8 |
regulated kinase | 8 |
juxtaglomerular apparatus | 8 |
ras within | 8 |
disulfide bridge | 8 |
tgn endosome | 8 |
phase i | 8 |
ii actions | 8 |
findings indicate | 8 |
del sraa | 8 |
human disease | 8 |
pressure effects | 8 |
including hypertension | 8 |
hepatic stellate | 8 |
human liver | 8 |
therapeutic approaches | 8 |
dss treatment | 8 |
ace i | 8 |
mild cases | 8 |
injury induced | 8 |
pharmacological inhibition | 8 |
ii induced | 8 |
recent advances | 8 |
vascular effects | 8 |
kidney cortex | 8 |
tumour necrosis | 8 |
gut microbiome | 8 |
patients admitted | 8 |
neurodegenerative disorders | 8 |
mediated increase | 8 |
recent findings | 8 |
kidney cells | 8 |
pilot study | 8 |
virus receptor | 8 |
idiopathic pulmonary | 8 |
grade soluble | 8 |
hypertrophic markers | 8 |
conformational analysis | 8 |
fusion protein | 8 |
study demonstrated | 8 |
national institutes | 8 |
altered blood | 8 |
cell body | 8 |
randomised trial | 8 |
decreased levels | 8 |
type internalization | 8 |
clinical findings | 8 |
tissue growth | 8 |
ncov infected | 8 |
ras inhibition | 8 |
peptidyl dipeptidase | 8 |
palmitic acid | 8 |
systemic ang | 8 |
map kinases | 8 |
upregulate ace | 8 |
hydrogen bonding | 8 |
tau pathology | 8 |
specific substrate | 8 |
umbilical cord | 8 |
membrane ace | 8 |
cells transfected | 8 |
cellular entry | 8 |
ace converts | 8 |
sodium pump | 8 |
physiological function | 8 |
testis ace | 8 |
ace induces | 8 |
new insights | 8 |
mechanisms involved | 8 |
life span | 8 |
drosophila melanogaster | 8 |
ace using | 8 |
deficiency accentuates | 8 |
protein level | 8 |
bowel disease | 8 |
northern italy | 8 |
cov spike | 8 |
ii angiotensin | 8 |
ncov may | 8 |
will allow | 8 |
cells via | 8 |
renin levels | 8 |
patients showed | 8 |
mice overexpressing | 8 |
pathological effects | 8 |
several new | 8 |
clinical implications | 8 |
alternative pathways | 8 |
final concentration | 8 |
pilot clinical | 8 |
emerging role | 8 |
described previously | 8 |
fibrotic effects | 8 |
ge healthcare | 8 |
patients linked | 8 |
ace concentrations | 8 |
peptide dendrimers | 8 |
either ace | 8 |
vasoactive peptides | 8 |
renal damage | 8 |
nep expression | 8 |
dysregulated ras | 8 |
sars cov | 8 |
xo expression | 8 |
transmembrane serine | 8 |
chronic obstructive | 8 |
afferent arterioles | 8 |
new target | 8 |
electron microscopy | 8 |
selective inhibitor | 8 |
mediated activation | 8 |
also called | 8 |
apelin antagonizes | 8 |
forming enzyme | 8 |
therapeutic approach | 8 |
prostaglandin synthesis | 8 |
adverse outcomes | 8 |
heavy chain | 8 |
human vsels | 8 |
also bind | 8 |
renin expression | 8 |
local ang | 8 |
clinical use | 8 |
using clinical | 8 |
association study | 8 |
mechanism underlying | 8 |
ii activates | 8 |
slit diaphragm | 8 |
tumor angiogenesis | 8 |
results suggested | 8 |
pneumonia patients | 8 |
axis may | 8 |
descriptive study | 8 |
trizol reagent | 8 |
also expressed | 8 |
reticulum stress | 8 |
cell function | 8 |
ii alveolar | 8 |
main effector | 8 |
endocrine system | 8 |
ii level | 8 |
macrophage infiltration | 8 |
physiological effects | 8 |
positively charged | 8 |
forming ang | 8 |
patients taking | 8 |
markedly reduced | 8 |
induced nephropathy | 8 |
severe symptoms | 8 |
ii metabolism | 8 |
ace protects | 8 |
tissue samples | 8 |
disease pathogenesis | 8 |
pressor response | 8 |
receptor system | 8 |
therapeutic agent | 8 |
pathological remodeling | 8 |
cardiac arrhythmias | 8 |
germinal ace | 8 |
new components | 8 |
intracellular renin | 8 |
diabetic retinopathy | 8 |
biochemical indexes | 8 |
activity relationships | 8 |
xanthine oxidase | 8 |
research council | 7 |
ace results | 7 |
life sciences | 7 |
facilitates viral | 7 |
iconverting enzyme | 7 |
control mice | 7 |
situ hybridization | 7 |
may involve | 7 |
without ace | 7 |
interstitial fluid | 7 |
two decades | 7 |
opposing actions | 7 |
ras might | 7 |
randomized trial | 7 |
american college | 7 |
hypertension ace | 7 |
kidney tissue | 7 |
transcriptional regulation | 7 |
experimental heart | 7 |
monoclonal antibody | 7 |
pulmonary blood | 7 |
mice expressing | 7 |
induced endothelial | 7 |
new drugs | 7 |
cardiovascular homeostasis | 7 |
two separate | 7 |
across gestation | 7 |
media thickness | 7 |
lung cells | 7 |
antihypertensive effect | 7 |
hexxh zinc | 7 |
renal proximal | 7 |
metabolic pathways | 7 |
factor beta | 7 |
artery smooth | 7 |
lesser extent | 7 |
treg th | 7 |
diabetes infected | 7 |
primary structure | 7 |
specific ang | 7 |
three different | 7 |
yet known | 7 |
small rnas | 7 |
human tissue | 7 |
coagulation cascade | 7 |
kidney ace | 7 |
direct evidence | 7 |
reactive protein | 7 |
early studies | 7 |
transmembrane glycoprotein | 7 |
chemical ligation | 7 |
specific expression | 7 |
alternative renin | 7 |
proteins involved | 7 |
furin cleavage | 7 |
systemic blood | 7 |
rat lung | 7 |
cv system | 7 |
catalytic domains | 7 |
neutralizing antibodies | 7 |
nonpeptide mimic | 7 |
chloride channel | 7 |
artery occlusion | 7 |
type natriuretic | 7 |
fat diet | 7 |
mouse heart | 7 |
large hinge | 7 |
statistically significantly | 7 |
amyloid angiopathy | 7 |
inflammatory effect | 7 |
serum albumin | 7 |
ii blockade | 7 |
using ace | 7 |
ii exerts | 7 |
adam activity | 7 |
plaque formation | 7 |
ras genes | 7 |
well plates | 7 |
increased cardiac | 7 |
bradykinin peptides | 7 |
infected pneumonia | 7 |
studies revealed | 7 |
healthy subjects | 7 |
class i | 7 |
peptide ligation | 7 |
recent report | 7 |
zinc metallopeptidase | 7 |
novel human | 7 |
pharmacokinetic properties | 7 |
using trizol | 7 |
drug candidates | 7 |
pcr analysis | 7 |
genetic analysis | 7 |
dd genotype | 7 |
molecular mechanism | 7 |
confocal microscopy | 7 |
endogenous peptide | 7 |
cell activation | 7 |
cerebral artery | 7 |
inhibitors angiotensin | 7 |
mediated vasodilation | 7 |
unlike ace | 7 |
derived tgf | 7 |
cardiac renin | 7 |
membrane aminopeptidase | 7 |
lysis buffer | 7 |
increased circulating | 7 |
receptor mediates | 7 |
negative bacteria | 7 |
enzyme determines | 7 |
unnatural amino | 7 |
diseases including | 7 |
proinflammatory cytokine | 7 |
might contribute | 7 |
mas angiotensin | 7 |
research groups | 7 |
processing enzymes | 7 |
vascular tone | 7 |
renal ras | 7 |
underlying mechanisms | 7 |
membranous nephropathy | 7 |
potential mechanism | 7 |
present work | 7 |
enzymatic degradation | 7 |
peptide libraries | 7 |
different types | 7 |
sprague dawley | 7 |
ii administration | 7 |
linear peptide | 7 |
years ago | 7 |
angiotensin angiotensin | 7 |
human body | 7 |
independent mechanisms | 7 |
influenza infection | 7 |
myocyte hypertrophy | 7 |
apical membrane | 7 |
obstructive pulmonary | 7 |
reduced plasma | 7 |
reduce ace | 7 |
activity may | 7 |
arterial remodeling | 7 |
animal care | 7 |
aldosterone release | 7 |
albumin excretion | 7 |
signal pathway | 7 |
immunocytochemical expression | 7 |
key regulator | 7 |
wall thickness | 7 |
normal human | 7 |
may induce | 7 |
rat lungs | 7 |
damage caused | 7 |
regulate ace | 7 |
ventricular mass | 7 |
survival study | 7 |
adult tissues | 7 |
baroreflex function | 7 |
leading cause | 7 |
antithrombotic activity | 7 |
enzymatically active | 7 |
pressure reduction | 7 |
ray structures | 7 |
lamina propria | 7 |
nucleic acid | 7 |
plasma clearance | 7 |
ards induced | 7 |
nmr studies | 7 |
prospective study | 7 |
since ang | 7 |
mouse brain | 7 |
antiproliferative activity | 7 |
low doses | 7 |
bnp mrna | 7 |
experimental evidence | 7 |
mouse embryonic | 7 |
vitro study | 7 |
cardioprotective actions | 7 |
small molecules | 7 |
diastolic dysfunction | 7 |
white blood | 7 |
study found | 7 |
hfmd patients | 7 |
chronic renal | 7 |
prone spontaneously | 7 |
systemic circulation | 7 |
adult respiratory | 7 |
lung tissues | 7 |
also reported | 7 |
feb administration | 7 |
human blood | 7 |
additional file | 7 |
coronavirus sars | 7 |
agonist ave | 7 |
may act | 7 |
i transmembrane | 7 |
reduces blood | 7 |
kinase pathway | 7 |
ace differentially | 7 |
apelin receptor | 7 |
counterregulatory actions | 7 |
proliferative effects | 7 |
enhanced renal | 7 |
human cardiac | 7 |
ischemic cardiomyopathy | 7 |
converting ang | 7 |
angiotensin production | 7 |
control study | 7 |
mitochondrial dysfunction | 7 |
studies also | 7 |
disease model | 7 |
circumventricular organs | 7 |
ras blockers | 7 |
bar chart | 7 |
rat hypothalamo | 7 |
enzyme inhibits | 7 |
experimental colitis | 7 |
molecular cloning | 7 |
fluid balance | 7 |
decrease ang | 7 |
cardiac tissues | 7 |
biological role | 7 |
two amino | 7 |
may attenuate | 7 |
structures reveal | 7 |
induces endothelial | 7 |
biliary fibrosis | 7 |
hemolytic activity | 7 |
serum uric | 7 |
potential mechanisms | 7 |
cardiovascular regulation | 7 |
endothelial ace | 7 |
using lc | 7 |
experimental acute | 7 |
ii significantly | 7 |
linked mental | 7 |
abundantly expressed | 7 |
pharmacological effects | 7 |
muscle actin | 7 |
express ace | 7 |
pregnant rats | 7 |
cardiovascular disorders | 7 |
em structure | 7 |
weight gain | 7 |
inhibitor omapatrilat | 7 |
pulmonary inflammation | 7 |
vascular remodelling | 7 |
peptidase activity | 7 |
gene knockout | 7 |
highest levels | 7 |
reduced expression | 7 |
renal renin | 7 |
still unclear | 7 |
heart cell | 7 |
increase blood | 7 |
hypertrophy induced | 7 |
may exert | 7 |
low molecular | 7 |
pressure homeostasis | 7 |
endothelial progenitor | 7 |
oral administration | 7 |
chronic hepatitis | 7 |
cultured rat | 7 |
myocardial hypertrophy | 7 |
lactam bridge | 7 |
zinc metallopeptidases | 7 |
embryonic stem | 7 |
ab operation | 7 |
cell penetrating | 7 |
excessive activation | 7 |
sfrp overexpression | 7 |
synthetic peptide | 7 |
vasoactive peptide | 7 |
peptide formation | 7 |
subsequent study | 7 |
improve outcomes | 7 |
results obtained | 7 |
middle cerebral | 7 |
may reflect | 7 |
aged apelin | 7 |
renal ischemia | 7 |
neurohypophysial system | 7 |
mtt assay | 7 |
takes place | 7 |
neutralizing activity | 7 |
blood sampling | 7 |
different species | 7 |
ace receptors | 7 |
molecular basis | 7 |
fold lower | 7 |
dd polymorphism | 7 |
inhibitors increase | 7 |
shear stress | 7 |
lipoprotein receptor | 7 |
therapeutic effects | 7 |
renal immunocytochemical | 7 |
messenger rna | 7 |
pulmonary injury | 7 |
confidence interval | 7 |
infarction increases | 7 |
peptides containing | 7 |
terminal dipeptide | 7 |
producing fusion | 7 |
i arbs | 7 |
oral delivery | 7 |
risk patients | 7 |
human breast | 7 |
microbial ecology | 7 |
system activation | 7 |
chart showing | 7 |
kg day | 7 |
also reduced | 7 |
heart angiotensin | 7 |
reproductive system | 7 |
since ace | 7 |
related proteins | 7 |
bending motion | 7 |
biological actions | 7 |
ace homologue | 7 |
ill covid | 7 |
antiviral response | 7 |
pulmonary ace | 7 |
bat origin | 7 |
also involved | 7 |
evidence supporting | 7 |
homologous domains | 7 |
recently shown | 7 |
mas knockout | 7 |
china clinical | 7 |
intravascular coagulation | 7 |
cysteine protecting | 7 |
relatively high | 7 |
aspartic acid | 7 |
differential expression | 7 |
hospital admission | 7 |
dependent vasodilatation | 7 |
motion important | 7 |
cleave ace | 7 |
higher ace | 7 |
potent inhibitor | 7 |
polyclonal antibody | 7 |
physiological relevance | 7 |
fmoc tbu | 7 |
important regulator | 7 |
two forms | 7 |
en pacientes | 7 |
significant changes | 7 |
higher ang | 7 |
will discuss | 7 |
mainly expressed | 7 |
murine bone | 7 |
ace variants | 7 |
genomic characterization | 7 |
renin release | 7 |
lung edema | 7 |
segmental glomerulosclerosis | 7 |
prokaryotic selectivity | 7 |
ace structure | 7 |
peptide sequences | 7 |
patients might | 7 |
enzyme responsible | 7 |
vascular diseases | 7 |
via inhibition | 7 |
strong evidence | 6 |
urinary albumin | 6 |
calcium signaling | 6 |
mice exhibited | 6 |
regulates blood | 6 |
pulmonary inflammatory | 6 |
stat pathway | 6 |
particularly relevant | 6 |
third trimester | 6 |
molecular size | 6 |
renin inhibition | 6 |
inhibitor cocktail | 6 |
derived vsels | 6 |
measured per | 6 |
causes severe | 6 |
acid sequences | 6 |
inhibitor mln | 6 |
ii binding | 6 |
outbreak associated | 6 |
mediated pressor | 6 |
canine coronary | 6 |
human hearts | 6 |
ii expression | 6 |
steroidal anti | 6 |
endogenous inhibitor | 6 |
standard therapy | 6 |
length form | 6 |
downstream signalling | 6 |
human genome | 6 |
tractus solitarii | 6 |
podocyte depletion | 6 |
enzyme inhibitory | 6 |
blood glucose | 6 |
may offer | 6 |
focal segmental | 6 |
ncov spike | 6 |
immunodeficiency virus | 6 |
commons licence | 6 |
ace substrate | 6 |
results indicate | 6 |
hydrolyzes ang | 6 |
renal cells | 6 |
month exposed | 6 |
altered glycosylation | 6 |
sars outbreak | 6 |
much less | 6 |
structure analysis | 6 |
bovine aortic | 6 |
central angiotensin | 6 |
new potential | 6 |
specific angiotensin | 6 |
increasing local | 6 |
heart contractility | 6 |
chronic administration | 6 |
degrading ang | 6 |
cell biology | 6 |
acid release | 6 |
spinal cord | 6 |
tissues including | 6 |
surface receptors | 6 |
conformational change | 6 |
study using | 6 |
virus transmission | 6 |
factor kappa | 6 |
potent anti | 6 |
may affect | 6 |
mediated cardiac | 6 |
effects mediated | 6 |
spike receptor | 6 |
reduced left | 6 |
human research | 6 |
mechanisms regulating | 6 |
induced injury | 6 |
mediated ace | 6 |
myocardial infarcted | 6 |
case report | 6 |
immune complex | 6 |
vasopeptidase inhibition | 6 |
low concentration | 6 |
receptors form | 6 |
potential approach | 6 |
nep levels | 6 |
poorly understood | 6 |
baroreflex control | 6 |
female reproductive | 6 |
ncov sars | 6 |
cotransporter activity | 6 |
vascular cells | 6 |
experimental hypertension | 6 |
peptide chain | 6 |
insulin secretion | 6 |
hypoxic pulmonary | 6 |
gram positive | 6 |
remain unclear | 6 |
cerebral amyloid | 6 |
research group | 6 |
ace leads | 6 |
sars patients | 6 |
hospitalized covid | 6 |
drug administration | 6 |
fibroblast proliferation | 6 |
possible involvement | 6 |
thrombus formation | 6 |
ad compared | 6 |
calculated using | 6 |
adrenergic receptor | 6 |
controlled study | 6 |
weight ratio | 6 |
cardiac output | 6 |
arb drugs | 6 |
collagen synthesis | 6 |
ace acts | 6 |
system date | 6 |
human subjects | 6 |
dimensional structure | 6 |
active ace | 6 |
target organ | 6 |
promotes antithrombotic | 6 |
gastric cancer | 6 |
large body | 6 |
elevated ace | 6 |
acute cardiac | 6 |
subsequent ang | 6 |
general hospital | 6 |
protease inhibitors | 6 |
low dose | 6 |
signaling mechanisms | 6 |
intracellular angiotensin | 6 |
will present | 6 |
turn structure | 6 |
combined treatment | 6 |
financial support | 6 |
also confirmed | 6 |
cells within | 6 |
caudal ventrolateral | 6 |
dna sequences | 6 |
ace amplification | 6 |
peptide receptor | 6 |
vivo metabolism | 6 |
complex system | 6 |
nonproteolytic activation | 6 |
alternative pathway | 6 |
podocytes cultured | 6 |
differentially interact | 6 |
selective overexpression | 6 |
vehicle treatment | 6 |
protective ang | 6 |
shr kidney | 6 |
perivascular fibrosis | 6 |
vasopeptidase inhibitors | 6 |
human urine | 6 |
bradykinin receptor | 6 |
microwave irradiation | 6 |
disseminated intravascular | 6 |
rna virus | 6 |
terminal glycosylation | 6 |
renal impairment | 6 |
organ injury | 6 |
vasoprotective axis | 6 |
sectional area | 6 |
colitis model | 6 |
using different | 6 |
expressed ace | 6 |
trend towards | 6 |
associated coronavirus | 6 |
ace level | 6 |
specific tissues | 6 |
specific protein | 6 |
vasopeptidase inhibitor | 6 |
biochemical pathways | 6 |
month smoke | 6 |
reduced levels | 6 |
viral shedding | 6 |
kinin peptide | 6 |
severe respiratory | 6 |
supplementary table | 6 |
rats reduces | 6 |
nucleic acids | 6 |
biological evaluation | 6 |
pediatric kidney | 6 |
egf receptor | 6 |
shed light | 6 |
rats treated | 6 |
might provide | 6 |
canonical wnt | 6 |
another important | 6 |
clinical manifestations | 6 |
pe group | 6 |
novel target | 6 |
single residue | 6 |
glomerular podocyte | 6 |
alternative axis | 6 |
arterial blood | 6 |
cardiovascular pathologies | 6 |
chronic inflammation | 6 |
activity studies | 6 |
truncated form | 6 |
genetic variants | 6 |
animal experiments | 6 |
termed ace | 6 |
weight kininogen | 6 |
mainly due | 6 |
augments entry | 6 |
use committee | 6 |
digestive system | 6 |
significantly elevated | 6 |
systemic vascular | 6 |
coronavirus replication | 6 |
proximal straight | 6 |
specific binding | 6 |
bradykinin peptide | 6 |
findings support | 6 |
pyrococcus furiosus | 6 |
enhanced chemiluminescence | 6 |
two groups | 6 |
last years | 6 |
una mayor | 6 |
brain ace | 6 |
mediated relaxation | 6 |
isolated using | 6 |
collagen iii | 6 |
acute renal | 6 |
regulate blood | 6 |
nonpeptide angiotensin | 6 |
early stage | 6 |
randomised controlled | 6 |
different populations | 6 |
extracellular fluid | 6 |
also induce | 6 |
water absorption | 6 |
acute coronary | 6 |
amino terminal | 6 |
potent inhibitors | 6 |
cirrhotic patients | 6 |
limiting step | 6 |
acid peptide | 6 |
human glomerular | 6 |
higher doses | 6 |
hw bw | 6 |
helical structure | 6 |
mg day | 6 |
long time | 6 |
accumulating evidence | 6 |
intrarenal angiotensin | 6 |
activation via | 6 |
serial changes | 6 |
fold increase | 6 |
thick ascending | 6 |
water reabsorption | 6 |
cell cycle | 6 |
enhanced ang | 6 |
dendritic cells | 6 |
gut microbiota | 6 |
total protein | 6 |
new analogues | 6 |
chronic treatment | 6 |
atp ap | 6 |
attenuates pulmonary | 6 |
collagen deposition | 6 |
signaling molecules | 6 |
accessory proteins | 6 |
protein priming | 6 |
peptides derived | 6 |
increased mortality | 6 |
osmotic minipumps | 6 |
downstream signaling | 6 |
important mechanism | 6 |
entry driven | 6 |
increased serum | 6 |
lv ejection | 6 |
trna fragments | 6 |
three main | 6 |
days post | 6 |
mas oncogene | 6 |
lewis rats | 6 |
nucleotide polymorphisms | 6 |
improved metabolic | 6 |
transgenic ren | 6 |
adult patients | 6 |
previous reports | 6 |
membrane vesicles | 6 |
oncogene mas | 6 |
regulated membrane | 6 |
many questions | 6 |
considered significant | 6 |
enzyme activators | 6 |
study reported | 6 |
ii feb | 6 |
anova followed | 6 |
developmentally regulated | 6 |
full length | 6 |
murine recombinant | 6 |
fluid volume | 6 |
key enzyme | 6 |
act via | 6 |
induced hypertensive | 6 |
xo activity | 6 |
ras peptides | 6 |
renal tissue | 6 |
resveratrol protects | 6 |
several different | 6 |
phase method | 6 |
mice carrying | 6 |
severe coronavirus | 6 |
van der | 6 |
glial cells | 6 |
promising candidates | 6 |
university hospital | 6 |
several mechanisms | 6 |
blood cell | 6 |
two independent | 6 |
positive bacteria | 6 |
plasma volume | 6 |
also increases | 6 |
host immune | 6 |
considered statistically | 6 |
trypsin inhibitor | 6 |
hydroxyeicosatetraenoic acid | 6 |
remains elusive | 6 |
pneumonia outbreak | 6 |
directed mutagenesis | 6 |
inflammatory conditions | 6 |
tract infections | 6 |
sodium excretion | 6 |
dna gyrase | 6 |
microvascular endothelial | 6 |
sickle cell | 6 |
vivo heart | 6 |
actions via | 6 |
derived peptides | 6 |
enzyme levels | 6 |
nasal epithelium | 6 |
lcz group | 6 |
previously demonstrated | 6 |
mesenchymal cells | 6 |
antifibrotic effects | 6 |
components required | 6 |
leukocyte recruitment | 6 |
dp dt | 6 |
new roles | 6 |
hypertension hospitalized | 6 |
probable bat | 6 |
wistar rats | 6 |
prevent lung | 6 |
natural amino | 6 |
system revisited | 6 |
regulated kinases | 6 |
tissue inflammation | 6 |
renal effects | 6 |
human pulmonary | 6 |
fibrosis induced | 6 |
distinct roles | 6 |
receptor mrna | 6 |
mhc ratio | 6 |
negatively regulates | 6 |
ace cleavage | 6 |
kininase ii | 6 |
higher affinity | 6 |
acid aspiration | 6 |
induced obesity | 6 |
terminal active | 6 |
ischaemic stroke | 6 |
stellate cells | 6 |
pulmonary angiotensin | 6 |
rat aorta | 6 |
concentration increases | 6 |
native chemical | 6 |
ace antibody | 6 |
vasodepressor actions | 6 |
dna synthesis | 6 |
renal tissues | 6 |
wnt signaling | 6 |
african americans | 6 |
receptor recognition | 6 |
vascular events | 6 |
also express | 6 |
drugs may | 6 |
newly discovered | 6 |
ut mice | 6 |
key step | 6 |
virus replication | 6 |
ii antagonism | 6 |
peptide chains | 6 |
normal conditions | 6 |
recent meta | 6 |
vascular cell | 6 |
atpase activity | 6 |
take place | 6 |
losartan administration | 6 |
chain cyclization | 6 |
receptor mediated | 6 |
lead compounds | 6 |
arterial stiffness | 6 |
hydrophobic interactions | 6 |
patients requiring | 6 |
neprilysin inhibitors | 6 |
clinical outcome | 6 |
camostat mesylate | 6 |
artery remodeling | 6 |
mechanism involving | 6 |
membrane proteins | 6 |
rats exposed | 6 |
possible mechanisms | 6 |
increased renal | 6 |
expression analysis | 6 |
intestinal ace | 6 |
results may | 6 |
synthetic peptides | 6 |
key factor | 6 |
rat uterus | 6 |
hemoregulatory peptide | 6 |
glucose transport | 6 |
also demonstrated | 6 |
prorenin levels | 6 |
hela cells | 6 |
induces vascular | 6 |
many different | 6 |
cardiopulmonary protection | 6 |
cells express | 6 |
shr rats | 6 |
also present | 6 |
high molecular | 6 |
ii regulates | 6 |
mas expression | 6 |
pathological hypertrophy | 6 |
provide evidence | 6 |
written informed | 6 |
viral binding | 6 |
lung epithelial | 6 |
clinical practice | 6 |
pregnancy group | 6 |
rat aortic | 6 |
investigate whether | 6 |